Protriptyline

Limits on what this shows

• Key negative/null findings: Desipramine was tested only in vitro, not in the mouse arm; no human mitochondrial-function biomarker data exist for any TCA including protriptyline.
• At-risk subgroups: None defined for protriptyline specifically; theoretical only.
• Counter-evidence on record: None identified; no published study reports a null mitochondrial-structure finding for any TCA.

Regulatory status

Not addressed in the FDA Vivactil label; no mitochondrial-toxicity warning for protriptyline.

Population evidence

Class extrapolation (Tier C) - protriptyline not in the studied cohort. Human SH-SY5Y neuroblastoma cells exposed to desipramine 50 micromolar for 24 hours showed a JC-1 fluorescence shift (red to green) indicating collapsed mitochondrial membrane potential and MitoTracker-documented mitochondrial fragmentation, p<0.01 to p<0.001 vs. vehicle. A parallel in vivo arm in C57BL/6 mice (n=5/group, amitriptyline 20 mg/kg twice weekly x4 weeks; desipramine not tested in vivo) showed consistent mitochondrial injury markers.

Mechanism

Direct mitochondrial structural injury (fragmentation, membrane depolarization, Bax activation) demonstrated for two TCA-class members (desipramine, amitriptyline); plausible but unconfirmed extension to protriptyline, a pharmacologically similar secondary-amine TCA.

Counter-evidence held on record

Framing caution Cell-line and rodent data only, from a different TCA, not protriptyline. This is a theoretical, class-level signal, not a confirmed clinical mitochondrial effect of protriptyline, and does not support any supplement recommendation.

Limits on what this shows

• Key negative/null findings: No systemic (serum) oxidative-stress marker (malondialdehyde, total antioxidant capacity) has been reported for any TCA including protriptyline in a human cohort located during this review.
• At-risk subgroups: None defined for protriptyline; theoretical only.
• Counter-evidence on record: None identified for this specific endpoint.

Regulatory status

Not addressed in the FDA Vivactil label.

Population evidence

Class extrapolation (Tier C). Same source as Mitochondrial burden above: "both amitriptyline and desipramine promoted the generation of ROS" in SH-SY5Y cells (desipramine 50 micromolar/24h) and in the mouse liver/brain arm (amitriptyline 20 mg/kg biweekly x4 weeks, n=5/group).

Mechanism

Mitochondrial-membrane injury driving reactive oxygen species generation, demonstrated for desipramine and amitriptyline; not tested for protriptyline.

Counter-evidence held on record

Framing caution This is a cell/animal-model signal from a different TCA. It is not evidence that protriptyline raises systemic oxidative stress in patients, and does not support an antioxidant-supplement recommendation.

Limits on what this shows

• Key negative/null findings: Brain copper (hippocampus, cerebellum, and other regions assessed) was unchanged by imipramine; only electroconvulsive shock, a non-pharmacologic comparator, raised regional brain copper. This null brain finding is an important counter-point against assuming a tissue-level copper deficit.
• At-risk subgroups: None defined for protriptyline; the source is a rat model, not a human cohort.
• Counter-evidence on record: Brain copper unaffected (see above); citalopram, a non-TCA, produced the same serum effect, weakening the specificity of the signal to the TCA mechanism and suggesting a more general antidepressant-exposure effect rather than a TCA-specific one.

Regulatory status

Not addressed in the FDA Vivactil label or any protriptyline-specific reference located.

Population evidence

Class extrapolation (Tier C) - protriptyline not in the studied cohort. Schlegel-Zawadzka & Nowak, Biological Trace Element Research (2000), rat study: chronic imipramine and citalopram (but not electroconvulsive shock) each significantly lowered serum copper by about 14%; overall brain copper was not altered by either drug.

Mechanism

Not established; the source reports the serum effect without a defined molecular mechanism.

Counter-evidence held on record

Framing caution Animal data from a different drug (imipramine), with a comparable effect also seen with a non-TCA (citalopram). This does not establish that protriptyline lowers copper in humans, and does not support copper supplementation, which has its own toxicity risk (NIH ODS adult UL for copper is 10,000 mcg/day) and is not indicated by this finding in any case.

Limits on what this shows

• Key negative/null findings: No placebo or drug-free comparison arm; this is a within-imipramine-cohort comparison (symptomatic vs. non-symptomatic patients on the same drug), not a drug-vs-no-drug design, so confounding by who develops jitteriness cannot be excluded.
• At-risk subgroups: Theoretical only for protriptyline; in the source population, patients with panic disorder who developed TCA-induced jitteriness.
• Counter-evidence on record: Active-comparator/no-placebo limitation stated above; sample sizes in both reports are small (letter-format publications), limiting generalizability.

Regulatory status

Not addressed in the FDA Vivactil label; the StatPearls and LiverTox protriptyline references do not mention iron.

Population evidence

Class extrapolation (Tier C) - protriptyline not in the studied cohort. Yeragani et al., J Clin Psychopharmacol 1989;9(6):447 ("Low Serum Iron Levels and Tricyclic Antidepressant-Induced Jitteriness") and Yeragani et al., Neuropsychobiology 1992;25(1):8-10 ("Imipramine-Induced Jitteriness and Decreased Serum Iron Levels"): in imipramine-treated panic-disorder patients, those who developed jitteriness had significantly lower serum iron than those who did not (p=0.01 in the second report). Both are short reports/letters in small psychiatric samples, not large cohort studies.

Mechanism

Not established; the authors note jitteriness/akathisia-like restlessness resembles a low-iron motor-restlessness picture (as seen in restless-legs syndrome) and hypothesize a shared iron-related pathway, but this is not confirmed.

Counter-evidence held on record

Framing caution Small, uncontrolled human reports in a different TCA, correlational rather than causal, and not replicated in protriptyline. Jitteriness itself is a motor side effect, not a marker of iron status, and must not be treated as iron deficiency on its own (Hard Rule 2); do not supplement iron based on this entry without an independent iron-deficiency workup.

Limits on what this shows

• Key negative/null findings: In vitro concentrations do not necessarily reflect gut luminal drug concentrations in vivo; no human stool-microbiome study of any TCA was located during this review.
• At-risk subgroups: None defined for protriptyline; theoretical only.
• Counter-evidence on record: Effects varied by bacterial species and by drug; not every antidepressant tested, and not every bacterial strain, showed meaningful inhibition.

Regulatory status

Not addressed in the FDA Vivactil label; TCAs are not classified as antimicrobials.

Population evidence

Class extrapolation (Tier C) - protriptyline not in the studied cohort. Ait Chait, Mottawea, Tompkins & Hammami, Scientific Reports 2020;10:17878: in vitro agar-diffusion and microbroth-dilution testing of six antidepressants (phenelzine, venlafaxine, desipramine, bupropion, aripiprazole, (S)-citalopram) against 12 gut-commensal bacterial strains. Desipramine showed the most potent antibacterial activity of the six, with minimum inhibitory concentrations of 75-800 micrograms/mL, most active against Akkermansia muciniphila, Bifidobacterium animalis, and Bacteroides fragilis, with viability reductions reaching five logarithmic orders at the concentrations tested.

Mechanism

Direct antibacterial activity against gut-commensal species, demonstrated for desipramine; not tested for protriptyline, though protriptyline shares desipramine's secondary-amine structural class.

Counter-evidence held on record

Framing caution In vitro data from a different TCA. This does not establish that protriptyline disrupts the human gut microbiome, and does not support probiotic supplementation as a protriptyline-specific recommendation.

Limits on what this shows

• Key negative/null findings: No whole-body or tissue-level ATP/energy-metabolism measurement exists for any TCA in humans in the sources located.
• At-risk subgroups: None defined for protriptyline; theoretical only.
• Counter-evidence on record: None identified.

Regulatory status

Not addressed in the FDA Vivactil label.

Population evidence

Class extrapolation (Tier C). Same source as above: "cellular ATP level decreased following the incubation with amitriptyline or desipramine" in SH-SY5Y cells, reported with p<0.01 to p<0.001 vs. vehicle.

Mechanism

Mitochondrial membrane depolarization and fragmentation (see Mitochondrial burden) plausibly reducing oxidative-phosphorylation capacity and cellular ATP yield, shown for desipramine/amitriptyline.

Counter-evidence held on record

Framing caution A cell-culture finding from a different TCA at a single fixed concentration, not a measurement of patient energy status. Does not support a CoQ10, creatine, or other "energy support" supplement claim for protriptyline.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C mechanistic or class-level evidence exists to support even a yellow grade, and no circulating consumer claim about protriptyline/TCAs and oxygen delivery, hemoglobin, or hematocrit was located to rebut as white.

Channels tried, PubMed

Search-listing query "tricyclic antidepressant hematocrit hemoglobin" via pubmed.ncbi.nlm.nih.gov/?term= returned a clean, explicit zero-result page ("No results were found," automatic term-mapping noted). This is a genuine literature-gap signal, not a tooling failure, for that specific phrasing.

Channels tried, Crossref

REST bibliographic search (api.crossref.org/works?query.bibliographic=tricyclic+antidepressant+hemoglobin+oxygen+affinity+erythrocyte) returned ten results, none involving any antidepressant or psychotropic drug; a clean, confirmed zero-relevant-result outcome.

Channels tried, blocked/tooling-limited

Semantic Scholar Graph API (both the search and the PMID-lookup endpoints) returned HTTP 429 on repeated attempts; Europe PMC REST API returned HTTP 429/proxy rate-limit refusal; the OpenAlex search endpoint (as opposed to its single-record lookup, used successfully elsewhere in this dossier) returned HTTP 429. These could not be ruled out as containing relevant material and this gap should be re-checked against them in a future revision.

Channels tried, label and consumer sources

FDA Vivactil PI, StatPearls, LiverTox, Drugs.com, and DrugBank contain no mention of hemoglobin, hematocrit, anemia-as-a-nutrient-marker, or oxygen delivery for protriptyline. GoodRx, Wikipedia (Tricyclic antidepressant), and WebMD (CoQ10 interactions, as a proxy check for general antidepressant-nutrient claim patterns) contained no circulating claim on this topic either.